The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

banner

OXiGENE Announces Issuance of US Patent for OXi4503 in Acute Myeloid Leukemia

31-May-2015 | Source : AG-IP News | Visits : 5351
SOUTH SAN FRANCISCO, Calif. – OXiGENE Inc., a biopharmaceutical company developing novel therapies for the treatment of cancer, announced in a press release that the US Patent and Trademark Office has granted it a patent (US Patent No. 9,040,500) related to the use of OXi4503 for the treatment of myeloid neoplasms, including acute myeloid leukemia (AML). 

"The granting of this US patent is a notable achievement for OXiGENE and strengthens our program in AML, a potential orphan indication for which there is a great unmet need," said Bill Schwieterman, M.D., OXiGENE's President and CEO. "We are looking forward to starting a new company-sponsored Phase 1/2 clinical study of OXi4503 for this indication later this year, as we work to advance and strengthen our clinical pipeline." 

OXi4503 (combretastatin A1 di-phosphate) is a dual mechanism vascular disrupting agent (VDA) that has been observed to block and destroy tumor vasculature, resulting in extensive tumor cell death and necrosis. OXi4503 combines a VDA mechanism with cytotoxic activity. It is currently being evaluated in a Phase 1 investigator-sponsored study at the University of Florida in patients with relapsed and refractory AML and myelodysplastic syndrome (MDS). The study is also sponsored in part by The Leukemia & Lymphoma Society's Therapy Acceleration Program. 

OXiGENE is planning to initiate a Phase 1/2 trial of OXi4503 in patients with AML and MDS later this year. About OXiGENE OXiGENE is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of cancer. The company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression. The company's lead clinical product candidate, fosbretabulin, is in development as a potential treatment for solid tumors. OXi4503, its second product candidate, is in development for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
 
share



Related Articles